Prof. Yue Ruan is a Ph.D. advisor from the Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences. He is recipient of the National Overseas Young Talent Scheme award. He earned his Ph.D. in Biomedical Engineering from the University of Cambridge’s Institute of Metabolic Science in 2017, under the mentorship of Professor Roman Hovorka, a Fellow of the UK Academy of Medical Sciences. From 2017 to 2021, Dr. Ruan was Research Associate at the Oxford Centre for Diabetes, Endocrinology, and Metabolism (OCDEM) and the Big Data Institute at the University of Oxford. From 2022 to late 2023, he served as Senior Research Scientist at Abbott Diabetes Care’s R&D division in the United States.

​As the first author, Prof. Yue Ruan has published over 40 SCI journal articles and abstracts in top medical/biomedical engineering journals such as Diabetes Care (IF=19.1), Diabetologia (IF=10.1), Diabetes (IF=9.5), Age&Aging (IF=10.7), Diabetes Obesity&Metabolism (IF=6.6), IEEE Transactions on Biomedical Engineering (IF=4.5), Computer Methods and Programs in Biomedicine (IF=5.4), and some of my achievements have been selected as hotspots and covers; As a core participant, I have published over 20 journal articles and abstracts in top medical journals such as the New England Journal of Medicine (IF=91.2), The Lancet (IF=79.3), and The Lancet Diabetes&Endocrinology (IF=32.1); In 2017, he presided over and participated in eight competitive scientific research projects, including "Personalization of glycomic regions to reduce in hospital hypoglycaemia" (the talent project between industry and Oxford University, UK, with a hit rate of 10%), medical devices - artificial pancreas research and development and its application in the diagnosis and treatment of type I and type II diabetes, with a total funding amount of more than 51 million yuan; He has been invited to participate in ADA, EASD, ATTD and other internationally renowned academic conferences on diabetes for 12 times and made academic reports; The research results of the clinical projects participated in have been reported multiple times by internationally renowned media such as BBC, Reuters, New York Times, Guardian, etc.

Application of wearable smart diagnostic and treatment management systems for chronic diseases (such as diabetes), applied mathematical modeling, statistics, control engineering, artificial intelligence, and computer simulation in medical intelligent diagnostics and treatment, along with the development of medical devices.

• Recipient of the National Natural Science Fund for Excellent Youth Grant, NSFC  (Overseas) Program
• '100 Talents Project' of Chinese Academy of Sciences
• B-class high level talent of Peacock Plan in ShenZhen GuangDong Province 

083100 Biomedical Engineering

081002 Signal and Information Processing

081203 Computer Application Technology

Research areas

Blood Glucose Monitoring , Machine Learning/Deep Learning, Applied Statistics, Control Engineering, Mathematical Modeling, Health Cloud Computing, Medical Devices, Wearable Health Devices

   

2013-10 to 2017-04
University of Cambridge (UK) — PhD Candidate

2010-09 to 2013-06
École Nationale Supérieure des Mines de Saint-Étienne (France) — Master's Degree

2008-09 to 2010-07
École Nationale Supérieure des Mines de Saint-Étienne (France) — Bachelor's Degree

Work Experience:

• 2024-01 to present: Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences
• 2022-07 to 2024-01: Senior Researcher at Abbott Diabetes Care, USA
• 2017-10 to 2022-06: Postdoctoral Researcher at the University of Oxford, UK
• 2017-04 to 2017-09: Postdoctoral Researcher at the University of Cambridge, UK
• 2014-12 to 2017-03: Assistant Researcher at the University of Cambridge, UK

Social Positions:

• 2023-01-01 to present: Youth Editorial Board Member of AJPS
• 2020-01-01 to present: Consultant at CamDiab, UK

   

（1） Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19: The CORONADO, ABCD COVID-19 UK national audit and AMERICADO study groups, DIABETES OBESITY & METABOLISM, 2023
（2） The impact of race/ethnicity on the clinical outcomes of people with type 2 diabetes admitted to hospital with COVID-19: an observational multi-national analysis, British Journal of Diabetes, 2023,
（3） A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID-19, DIABETES OBESITY & METABOLISM, 2023
（4） Increase in hypoglycaemia and hyperglycaemia in people with diabetes admitted to hospital during COVID-19 pandemic, JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023
（5） Real-World Evidence Analysis of a Hybrid Closed-Loop System, Journal of Diabetes Science and Technology, 2023
（6） Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19, DIABETES CARE, 2022
（7） Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study, DIABETES & METABOLIC SYNDROME: CLINICAL RESEARCH & REVIEWS, 2022
（8） The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19), CARDIOVASCULAR DIABETOLOGY, 2022
（9） Safety of User-Initiated Intensification of Insulin Delivery Using Cambridge Hybrid Closed-Loop Algorithm, Journal of Diabetes Science and Technology, 2022
（10） Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial, THE LANCET DIGITAL HEALTH, 2022,
（11） An audit of people admitted to hospitalwith diabetes and coronavirus (SARS-CoV-2):data collection methods. The Association of British Clinical Diabetologists (ABCD) Nationwide Audit, British Journal of Diabetes, 2021
（12） Day-to-day variability of insulin requirements in the inpatient setting: Observations during fully closed-loop insulin delivery, DIABETES OBESITY & METABOLISM, 2021
（13） COVID-19 outcomes in people with diabetes in Wales a secondary analysis of the ABCD audit, British Journal of Diabetes, 2021
（14） A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection, DIABETOLOGIA, 2021,
（15） Inpatient hypoglycaemia in older people is associated with a doubling in the increased length of stay compared with the younger population, AGE AND AGEING, 2021
（16） INPATIENT HYPOGLYCAEMIA - UNDERSTANDING WHO IS AT RISK, DIABETES TECHNOLOGY & THERAPEUTICS, 2020
（17） Predicting the Risk of Inpatient Hypoglycemia With Machine Learning Using Electronic Health Records, DIABETES CARE, 2020
（18） Inpatient hypoglycaemia: understanding who is at risk, DIABETOLOGIA, 2020
（19） Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area-under-curve of plasma C-peptide concentration, PEDIATRIC DIABETES, 2019
（20） Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes, DIABETES OBESITY & METABOLISM, 2019
（21） Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis, KIDNEY INTERNATIONAL, 2019
（22） Importance of inpatient hypoglycaemia: impact, prediction and prevention, DIABETIC MEDICINE, 2019
（23） Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes, DIABETES OBESITY & METABOLISM, 2018
（24） Application of Bayesian analysis to the doubly labelled water method for total energy expenditure in humans, RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2018
（25） A probabilistic soft alert method for abnormal glycemic event by quantitative analysis of prediction uncertainty for type 1 diabetes, CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2018
（26） Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care, NEW ENGLAND JOURNAL OF MEDICINE, 2018
（27） Bolusing frequency and amount impacts glucose control during hybrid closed-loop, DIABETIC MEDICINE, 2018
（28） Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial, THE LANCET, 2018, 
（29） Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial, JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2017
（30） Lorcaserin improves glycemic control via a melanocortin neurocircuit, MOLECULAR METABOLISM, 2017
（31） Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes, DIABETES OBESITY & METABOLISM, 2017
（32） Modeling Day-to-Day Variability of Glucose-Insulin Regulation Over 12-Week Home Use of Closed-Loop Insulin Delivery, IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2017,
（33） Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial, THE LANCET DIABETES & ENDOCRINOLOGY, 2017
（34） Serum metabolomics profiles in response to n-3 fatty acids in Chinese patients with type 2 diabetes: a double-blind randomised controlled trial, SCIENTIFIC REPORTS, 2016
（35） Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes, DIABETES CARE, 2016
（36） Modelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery, BIOMEDICAL ENGINEERING ONLINE,14,1(2015-03-04), 2015
（37） Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial, DIABETOLOGIA, 2015
（38） Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery, COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2014

An optical sensor, optical detection method, and storage medium, invention patent, 2023, 4th author, patent number: CN117530686A

Research Projects:

1. Intelligent Diabetes Analysis and Diagnosis (Principal Investigator), National Task, May 2024 – April 2027
2. CAS Talent Matching Project (Principal Investigator), Institute’s Independent Deployment, May 2024 – May 2027
3. ABCD Clinical Diabetes Physician Society Project (UK) (Principal Investigator), January 2020 – January 2023
4. Novo Nordisk University of Oxford Foundation Project (Principal Investigator), October 2017 – July 2020
5. EU Horizon 2020 Health Project (Participant), January 2017 – January 2020
6. National Institute for Health Research (Participant), January 2016 – January 2020

Collaborating Institutions:

Domestic:

• Medical and Health Institutions: Eastern Theater Command Air Force Hospital of the PLA, General Hospital of the PLA, Shenzhen People's Hospital, Shenzhen Second People's Hospital, First Affiliated Hospital of Sun Yat-sen University, Tongji Hospital of Shanghai, First Affiliated Hospital of Nanjing Medical University, Second Affiliated Hospital of Nanjing Medical University, Fourth Affiliated Hospital of Nanjing Medical University, and others.

• Universities/Research Institutes: Tsinghua University, Peking University, Shanghai Jiao Tong University, Sun Yat-sen University, Zhejiang University, Tongji University, Wuhan University, West Lake University, Southeast University, Nanjing University, Nanjing Medical University, Nanjing University of Technology, Institute of Automation, Chinese Academy of Sciences, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, and others.

Overseas:

• Harvard University, University of Oxford, University of Cambridge, Imperial College London, Ohio University, National Institute for Health Research (UK), ABCD Clinical Diabetes Physician Society (UK), Horizon Europe, Novo Nordisk, Abbott, and others.